Navigation Links
Neurocrine Biosciences Reports First Quarter 2013 Results
Date:5/2/2013

parallel-design, multiple-dose, six-week study assessing NBI-98854 against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the AIMS at the end of the six weeks of dosing. Top-line data from this placebo-controlled study is expected to closely follow the top-line results of the Kinect Study.

The Company anticipates an end of Phase II meeting for NBI-98854 in tardive dyskinesia to be held with the FDA in the fourth quarter of 2013.

Additionally, the Company has initiated a preclinical study to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of this preclinical study, the Company anticipates entering Phase I clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern TimeNeurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 866-952-1908 (US) or 785-424-1827 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-753-0348 (US) or 402-220-2672 (International) using the conference ID: NBIX. The call will be archived for one month.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, includ
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
2. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
3. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
4. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
5. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
6. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
7. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
11. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... SAN CLEMENTE, Calif., Jan. 23 Today the FDA ... Embryonic Stem Cells,but Adult Stem Cell scientist Christian Drapeau ... Adult Stem Cells have greater potential with less,risk. , ... an exciting step forward toward freeing science,from the shackles ...
... Rats Highlighted -PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ ... GENR ) today announced a poster presentation of ... candidate for the treatment of type 2 diabetes ... Novel Aspects of the Regulation of Body Weight ...
Cached Medicine Technology:FDA Stem Cell Approval Breakthrough Laudable 2Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 2Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable ... from 3 p.m. to 4 p.m. on Feb. 13. , The ... serves adults with physical disabilities between the ages of 22 and ... games and sweetheart-themed karaoke. , For more information about the event ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... CAMBRIDGE, Mass., Oct. 28 Biopure Corporation,(Nasdaq: ... a notice from the,Medicines Control Council (MCC) of ... of Hemopure [hemoglobin glutamer-250,(bovine)], Biopure,s oxygen therapeutic for ... intends to appeal the decision promptly and,expects to ...
... Periodontal disease rises as the joint ailment worsens, research ... arthritis (RA) may increase the risk of gum disease, ... a link between RA and periodontal disease, a condition ... teeth from the gums, loss of bony support, and ...
... NEWPORT BEACH, Calif., Oct. 28 Nationwide,Health Properties, Inc. ... of,Directors declared a $0.44 per share dividend on our ... to shareholders of record on November 14, 2008., ... per share,dividend on our Series B cumulative convertible preferred ...
... Oct. 28 IRIDEX,Corporation (Nasdaq: IRIX ) today ... results after the market closes on Tuesday, November,4, 2008. ... a,conference call with the investment community at 5:00 p.m. ... results of the quarter and other,business developments., Interested ...
... (TSX: RBM, OTCBB: RPBIF) (the "Company") today announced ... financing announced on October,14, 2008 and amended on ... The closing involved a brokered and non-brokered private ... for each unit. Each unit consisted,of one common ...
... 26, 2008) A single administration of a novel, nasally ... were more than 20 times higher than those generated ... to a study by NanoBio Corporation. The new vaccine ... this effect. , Results of the study are being ...
Cached Medicine News:Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 2Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 3Health News:Rheumatoid Arthritis May Harm Gums 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:New intranasal influenza vaccine triggers robust immunity with significantly less antigen 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: